Ateroesclerosis asociada a infección por chlamydophila pneumoniae: interacción entre el ser humano y una bacteria

Barra lateral del artículo

PDF HTML
Publicado: ene. 15, 2015
DOI: https://doi.org/10.21676/2389783X.1397
Palabras clave:
Aterosclerosis, Chlamydophila pneumoniae, Enfermedades Cardiovasculares

Contenido principal del artículo

Alvaro Gudiño-Gomezjurado
Hospital Regional del Instituto de Seguridad Social de Ibarra
Marco Gudiño-Gomezjurado
Universidad Complutense de Madrid

Resumen

La ateroesclerosis y sus complicaciones constituyen una de las mayores causas de morbi-mortalidad a nivel mundial. Sin embargo, solo la mitad de los casos se justifica por los factores de riesgo tradicionales. No obstante, desde hace casi cinco décadas se ha intentado encontrar causas no tradicionales asociadas a la enfermedad ateroesclerótica. Varios agentes infecciosos han emergido como posibles candidatos centralizándose la investigación en Chlamydophila pneumoniae por su capacidad de infectar las células endoteliales durante el proceso ateroesclerótico. A lo largo del tiempo, múltiples estudios han tratado de probar la causalidad de C. pneumoniae en el proceso ateroesclerótico y sus complicaciones. A pesar de esto, hasta la fecha las conclusiones son ambiguas y de poca relevancia para la práctica clínica diaria.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
Gudiño-Gomezjurado, A., & Gudiño-Gomezjurado, M. (2015). Ateroesclerosis asociada a infección por chlamydophila pneumoniae: interacción entre el ser humano y una bacteria. Duazary, 12(1), 41–48. https://doi.org/10.21676/2389783X.1397
Número
Vol. 12 Núm. 1 (2015): (enero - junio)
Sección
Artículo de revisión

No se permite un uso comercial de la obra original ni de las posibles obras derivadas, la distribución de las cuales se debe hacer con una licencia igual a la que regula la obra original.

Citas

Quinn TC. Does Chlamydia pneumoniae cause coronary heart disease?. Curr Opin Infect Dis. 1998 Jun;11 (3):301-7.

García-Elorriaga G, Del Rey-Pineda G. Human immunodeficiency virus, atherosclerosis and Chlamydophila pneumoniae. World J Clin Infect Dis. 2012 August 25; 2(4): 54-62.

Colombia. Instituto Nacional de Salud. Enfermedad cardiovascular, principal causa de muerte en Colombia. Boletín N° 1, (Diciembre 9 de 2013).

Dunne M. The evolving relationship between Chlamydia pneumoniae and atherosclerosis. Curr Opin Infect Dis. 2000 Dec;13(6):583-591.

Blasi F, Fagetti L, Allegra L. Chlamydia pneumoniae detection in atherosclerotic plaques in Italy. J Infect Dis. 2000 Jun;181 (Suppl 3):444-6.

Di Pietro M, Filardo S, De Santis F, Sessa R. Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview. Int J Mol Sci. 2013 Jul; 14(7):15105-20. doi: 10.3390/ijms140715105.

Wiesli P1, Maly FE, Meniconi A, Czerwenka W, Hoffmann U, Vetter W, et al. Chlamydia pneumoniae seropositivity and hyperhomocysteinemia are linked in patients with atherosclerosis. Clin Chem. 2001;47(7):1304-6.

Bayram A, Erdoğan MB, Ekşi F, Yamak B. Demonstration of Chlamydophila pneumoniae, Mycoplasma pneumoniae, Cytomegalovirus, and Epstein-Barr virus in atherosclerotic coronary arteries, nonrheumatic calcific aortic and rheumatic stenotic mitral valves by polymerase chain reaction. Anadolu Kardiyol Derg. 2011 May;11(3):237-43. doi: 10.5152/akd.2011.057. Epub 2011 Apr 5.

Gagliardi RJ1, Silveira DR, Caffaro RA, Santos VP, CaiaffaFilho HH. Chlamydia pneumoniae and symptomatic carotid atherosclerotic plaque: a prospective study.Arq Neuropsiquiatr. 2007 Jun;65(2B):385-9.

Joshi R, Khandelwal B, Joshi D, Gupta OP. Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci. 2013 Mar;5(3):169-81. doi: 10.4103/1947- 2714.109178.

Dean D, Neumayr L, Kelly DM, Ballas SK, Kleman K, Robertson S, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease.J Pediatr Hematol Oncol. 2003 Jan;25(1):46-55.

Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond). 2008 Apr;114(8):509-31. doi: 10.1042/CS20070298.

Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun. 1994 Sep;62 (9):3705-11.

Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007 Feb 15;44(4):568-76. Epub 2007 Jan 18.

Franco RR, Bodanese LC, Repetto G, Piccoli Jda C, Wiehe M, Bonato C, et al. Inflammatory markers and antichlamydial antibodies in patients with metabolic syndrome. Arq Bras Cardiol. 2011 Feb;96(2):134-9. Epub 2010 Nov 12.

Ljungh Å. Atherosclerosis and chlamydophila (chlamydia) pneumoniae. From friends to foes 2005: 23.

Benagiano M, Munari F, Ciervo A, Amedei A, Paccani SR, Mancini F, et al. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1222-7. doi: 10.1073/pnas.1111833109. Epub 2012 Jan 9.

Huang CY, Shih CM, Tsao NW, Chen YH, Li CY, Chang YJ, et al. GroEL1, from Chlamydia pneumoniae, induces vascular adhesion molecule 1 expression by p37(AUF1) in endothelial cells and hypercholesterolemic rabbit. PLoS One. 2012;7(8):e42808. doi: 10.1371/journal. pone.0042808. Epub 2012 Aug 10.

Chahine MN, Deniset J, Dibrov E, Hirono S, Blackwood DP, Austria JA, et al. Oxidized LDL promotes the mitogenic actions of Chlamydia pneumoniae in vascular smooth muscle cells. Cardiovasc Res. 2011 Dec 1;92(3):476-83. doi: 10.1093/cvr/cvr251.

Kreutmayer S, Csordas A, Kern J, Maass V, Almanzar G, Offterdinger M, et al. Chlamydia pneumoniae infection acts as an endothelial stressor with the potential to initiate the earliest heatshock protein 60-dependent inflammatory stage of atherosclerosis. Cell Stress Chaperones. 2013 May;18(3):259-68. doi: 10.1007/ s12192-012-0378-7.

Kalayoglu M, Byrne G. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;(177):725-9

Canducci F, Saita D, Foglieni C, Piscopiello MR, Chiesa R, Colombo A, et al. Cross-reacting antibacterial autoantibodies are produced within coronary atherosclerotic plaques of acutecoronary syndrome patients. PLoS One. 2012;7(8):e42283. doi: 10.1371/journal.pone.0042283. Epub 2012 Aug 6.

Nazmi A, Diez-Roux AV, Jenny NS, Tsai MY, Szklo M, Aiello AE. The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysisfrom the Multi-Ethnic Study of Atherosclerosis. BMC Public Health. 2010 Nov;10:706. doi: 10.1186/1471-2458-10-706.

Honarmand H. Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory.Interdiscip Perspect Infect Dis. 2013; 2013: 941392. doi: 10.1155/2013/941392. Epub 2013 Jul 17.

Chen J, Zhu M, Ma G, Zhao Z, Sun Z. Chlamydia pneumoniae infection and cerebrovascular disease: a systematic review and meta-analysis. BMC Neurol. 2013 Nov 21;13:183. doi: 10.1186/1471-2377-13-183.

Fallah F, Eslami G, Bootorabi M, Kazemi B, Goudarzi H, Mozaheri E. The isolation of chlamydia pneumoniae in atherosclerosis patients in Iran by PCR method. Gene Ther Mol Biol. 2000;10: 109-112.

Frishman WH, Ismail AA. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target?Cardiol Rev. 2002 Jul-Aug;10 (4):199-210.

Virok D, Kis Z, Karai L, Intzedy L, Burian K, Szabo A, et al. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke. 2001 Sep;32 (9):1973-6.

Zeman K, Pospíšil L, Čanderle J, Štroblová H, Leypold J, Gregor, et al. Direct and indirect evidence of chlamydia pneumoniae in patients with significant stenosis of a. Carotis of atherosclerotic origin. Scripta medica (Brno). 2004 Jun; 77 (3): 173–180.

Ramires JA, Higuchi Mde L. Mycoplasma pneumoniae and Chlamydia pneumoniae are associated to inflammation and rupture of the atherosclerotic coronary plaque. Rev Esp Cardiol. 2002;55 (S1):2-9.

Ieven MM, Hoymans VY. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol. 2005 Jan;43 (1):19-24.

Aalto-Setälä, Laitinen K, Erkkilä L, Leinonen M, Jauhiainen M, Ehnholm C. Chlamydia pneumoniae Does Not Increase Atherosclerosis in the Aortic Root of Apolipoprotein E–Deficient Mice. Vasc Biol Arterioscler 2001; 21:578-584.

Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999 Sep; 43 (9):2268-72.

Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol. 2003 Dec; 14(6):605-14.

Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999 Feb; 281 (5):427-31.

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis. 2000 Jun;181 (S3):563-5.

Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ. 2000 Jul 11;163 (1):49-56.

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis. 1999 Apr;5 (2):281-4.

Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis -- what we know and what we don’t. Clin Microbiol Infect. 2002 Jan; 8(1):2-13.

Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis--the case for Chlamydia pneumoniae. Clin Cardiol. 1997 Oct; 20(10):829-36.

Martin D, Bursill J, Qui MR, Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet. 1998 Jun 20;351 (9119):1858–1859.

Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002;(105):1555–60.

Scheller B, Hennen B, Markwirth T, Schieffer H. Evaluation of the role of Chlamydia pneumoniae in the pathogenesis of atherosclerosis - a review. J Clin Basic Cardiol 2000; 3: 155.

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005 Apr 21; 352(16):1637-45.

Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999 Mar 30; 99(12):1540-7.

Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; (361):809–13.

O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003; (290):1459–66.

Zahn R, Schneider S, Frilling B, et al. Antibiotic therapy after acute myocardial infarction: A prospective randomized study. Circulation. 2003;107: 1253–1259.

Leowattana W, Bhuripanyo K, Singhaviranon L, et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai. 2001; 84 (S3): S669–S675.

Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation. 2004 Mar;109(8):1010-5.

Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebocontrolled pilot study. J Vasc Surg. 2001; 34: 606–610.

Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001 Aug;88(8):1066-72.

Berg HF, Maraha B, Scheffer GJ, Quarles-van Ufford M, Vandenbroucke-Grauls CM, Peeters MF Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis. 2005 Feb 1;40(3):358-65.

Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).Circulation. 2002; 106: 1219–1223.

Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997 Dec 2;96 (11):4095-103.